Ftse Mib
34.157,82
0,50%
DAX
18.290,91
0,65%
S&P 500
5.180,74
0,00%
NASDAQ
16.349,25
0,00%
Bitcoin
63.613,58
0,71%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Takeda Pharmaceutical Company Ltd (TAK) Takeda Pharmaceutical Company Ltd (TAK) Notizie

Takeda Pharmaceutical Company Ltd

TAK
13,29
-0,07 (-0,52%)
Pre Mercato
Ultimo aggiornamento: 14:21:55
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/4/202414:30BWTakeda Receives Positive CHMP Opinion for Fruquintinib in..
23/4/202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
22/4/202410:10PRNUSTakeda, Astellas and Sumitomo Mitsui Banking Announce Master..
19/4/202401:00BWU.S. FDA Approves Subcutaneous Administration of Takeda’s..
08/4/202414:00BWTakeda Announces New U.S. Corporate Social Responsibility..
27/3/202413:56PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202413:53PRNUSEmpathy in Action: Takeda's Global Initiative Brings IBD..
27/3/202406:01BWTakeda gibt Kandidaten für den Vorstand bei der kommenden..
27/3/202400:07BW武田薬品工業: 第148回定時株主総会に提案する取締役候補者について
26/3/202413:00BWTakeda Announces Approval of ADZYNMA® Intravenous Injection..
21/3/202414:39BW武田薬品、Ph+..
21/3/202408:33BWTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch..
20/3/202420:18BWTakeda annonce l'approbation par la FDA des États-Unis d'une..
19/3/202417:20BWTakeda Announces U.S. FDA Approval of Supplemental New Drug..
19/3/202411:30GLOBECENTOGENE Extends Strategic Partnership With Takeda to..
13/3/202413:00BWTakeda Announces Positive Topline Results from Phase 2 Study..
28/2/202413:03BW武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力
27/2/202423:26BWTakeda et Biological E. Limited s’associent pour accélérer..
27/2/202413:38BWTakeda und Biological E. Limited arbeiten zusammen, um den..
27/2/202405:30BWTakeda and Biological E. Limited Collaborate to Accelerate..
26/2/202413:00PRNCAChampioning Rare Voices on Rare Disease Day
12/2/202414:00BWFDA Approves Takeda’s EOHILIA (budesonide oral suspension),..
09/2/202400:00BWTakeda Intends to Rapidly Initiate the First Global Phase 3..
01/2/202422:23BWTakeda gibt Nachfolger für die Position des Chief Financial..
01/2/202422:18BWTakeda annonce la succession de son directeur financier
01/2/202415:59BWTakeda gibt Ergebnisse für das dritte Quartal des..
01/2/202412:18EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202407:54BWTakeda Announces Chief Financial Officer Succession
01/2/202407:02BWTakeda Announces Third-Quarter FY2023 Results; On-Track..
30/1/202417:00BW武田薬品、慢性炎症性脱髄性多発根神経炎（CIDP）に対する維持療法としてのHYQVIA®について、欧州委員会から承認を獲得
30/1/202414:04BWTakeda-Arzneimittel HYQVIA ® von der Europäischen Kommission..
29/1/202419:55BWLe HYQVIA® de Takeda approuvé par la Commission européenne..
29/1/202417:10BWTakeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults..
29/1/202408:00BWTakeda’s HYQVIA® Approved by European Commission as..
25/1/202423:00PRNUSCognizant Helping to Modernize Infrastructure and..
25/1/202412:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202412:11EDGAR2Form SC 13D/A - General statement of acquisition of..
19/1/202412:03EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/1/202419:56BWTakeda est nommée Top Employer mondial pour la septième..
18/1/202419:45BW武田薬品工業、7年連続でトップ・エンプロイヤーに認定
18/1/202419:22BWTakeda im siebten Jahr in Folge international als Top..
18/1/202413:00BWTakeda Named Global Top Employer for Seventh Consecutive..
16/1/202414:00BWU.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in..
16/1/202412:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202322:00BWTakeda Announces China NMPA Approval of LIVTENCITY®..
20/12/202313:01PRNCATakeda Enters Into Two-Year Contract with Canadian Blood..
16/12/202317:36BWTakeda obtient l’avis favorable du CHMP pour HYQVIA® en tant..
16/12/202316:47BWTakeda erhält positive CHMP-Stellungnahme für HYQVIA® als..
15/12/202314:16BWTakeda Receives Positive CHMP Opinion for HYQVIA® as..
Apertura: Min: Max:
Chiusura: 13,36

La tua Cronologia

NYSE
TAK
Takeda Pharmaceutical
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network